Semaglutide: dose predicts CV outcomes

A study published 10 July 2026 in NPJ Cardiovascular Health found that cardiovascular outcomes in semaglutide-treated patients aligned more closely with the dose they reached than with how much weight they lost^[1]. The finding adds a new dimension to how researchers think about semaglutide's heart benefits, which were first established in the SELECT trial in 2023.

What the study found

Murugadoss et al. analysed 12,519 patients with pre-existing cardiovascular disease who had taken semaglutide^[1]. Patients who reached higher maximum doses showed substantially lower risks of subsequent cardiovascular events. The risk ratios were: all-cause mortality 0.42 (p < 0.001), composite cardiovascular events 0.51 (p < 0.001), cerebrovascular disease 0.50 (p < 0.001), and heart failure 0.55 (p < 0.001). Each 1 mg increase in maximum dose was associated with 3.15% additional weight loss.

The more striking finding was the negative one. When the researchers looked at achieved weight loss specifically, it showed no significant association with subsequent mortality (p = 0.14) or cardiovascular events (p = 0.55)^[1]. That held even though weight loss was, as expected, associated with improvements in HbA1c and blood pressure.

Why dose rather than weight loss

The authors conclude that semaglutide's cardiovascular protection appears to operate through pathways that are independent of, or at least not fully captured by, the scale of body-weight reduction. Proposed mechanisms in the literature include direct effects on cardiac and vascular tissue (GLP-1 receptors are expressed in the heart and blood vessels), anti-inflammatory actions, and favourable shifts in lipid profiles and blood pressure that may not be fully represented in a simple weight-loss number.

The GLP-1 receptor agonist class has accumulated evidence for direct cardioprotective effects since the early SUSTAIN trials in type 2 diabetes. Semaglutide's cardiovascular outcomes trial in diabetes, SUSTAIN-6 (Marso et al., NEJM 2016), found a statistically significant reduction in MACE in high-risk patients with type 2 diabetes. The SELECT trial extended that question to people who had cardiovascular disease but no diabetes, asking whether the drug's effects on the heart were independent of the glycaemia it was treating. The answer was yes. The Murugadoss paper asks a narrower version of the same question within the semaglutide-treated population itself.

This is not a new hypothesis. The SELECT trial^[2], which reported a 20% relative reduction in major adverse cardiovascular events in 17,604 overweight or obese adults without diabetes on semaglutide 2.4 mg versus placebo, was itself run partly because earlier animal and mechanistic data suggested semaglutide had cardiac effects beyond weight reduction. SELECT confirmed the benefit but was not designed to isolate the mechanism. This new analysis steps into that gap.

What this is not

This study is observational, not a randomised trial. Patients who reached higher doses may differ in ways the analysis cannot fully control for: they may have tolerated the drug better, had fewer competing illnesses, or had clinical teams that titrated more aggressively. The absence of a significant weight-loss association should not be read as evidence that weight loss on semaglutide is unimportant. The SELECT trial^[2] demonstrated a meaningful cardiovascular benefit across the full trial population, and that remains the most reliable evidence base for semaglutide's cardiac effect. What the Murugadoss paper adds is a signal that dose adequacy may be a more sensitive surrogate for that benefit than the number on the scale.

The study was published in NPJ Cardiovascular Health (Springer Nature) and is indexed at PubMed. It is not a prescribing guide, and the authors do not suggest that clinicians should treat dose attainment as the only goal. Titration is guided by tolerability and individual response, which is how the approved prescribing information frames it across all authorised presentations of semaglutide.

For readers in the EU and UK, semaglutide is authorised under Ozempic (type 2 diabetes) and Wegovy (weight management and cardiovascular risk reduction in overweight or obese adults)^[3]. The Wegovy indication explicitly includes adults with established cardiovascular disease, reflecting the SELECT data. This study does not alter that regulatory position but adds context to the clinical conversation about how the drug is achieving its cardiovascular effects.

Where this lands

For clinicians and patients tracking semaglutide, the practical implication of this study is modest but worth noting: the cardiovascular argument for staying on an adequate dose may be separate from the weight-management argument. Patients who lose less weight than expected on semaglutide are sometimes tempted to discontinue. If the drug's cardiac benefit is dose-dependent rather than weight-loss-dependent, that framing may be incomplete.

The SELECT trial remains the primary evidence source for semaglutide's cardiovascular outcomes^[2]. This new analysis does not replace it. It asks a finer question: within the population that took semaglutide, who did best? The answer, in this dataset, was the patients who reached higher doses. Whether that finding holds in prospective trials and whether it changes clinical practice will depend on replication. The study's DOI is 10.1038/s44325-026-00146-1.